Federated Investors Inc. PA reduced its position in GlaxoSmithKline (NYSE:GSK) by 14.7% in the first quarter, Holdings Channel reports. The institutional investor owned 4,292,194 shares of the pharmaceutical company’s stock after selling 740,665 shares during the period. Federated Investors Inc. PA’s holdings in GlaxoSmithKline were worth $167,696,000 as of its most recent SEC filing.
A number of other large investors have also recently bought and sold shares of GSK. Atria Investments LLC boosted its position in GlaxoSmithKline by 17.1% in the 4th quarter. Atria Investments LLC now owns 12,830 shares of the pharmaceutical company’s stock valued at $455,000 after buying an additional 1,874 shares during the last quarter. Acadian Asset Management LLC boosted its position in GlaxoSmithKline by 171.1% in the 4th quarter. Acadian Asset Management LLC now owns 44,668 shares of the pharmaceutical company’s stock valued at $1,585,000 after buying an additional 28,192 shares during the last quarter. Fox Run Management L.L.C. purchased a new position in GlaxoSmithKline in the 4th quarter valued at about $262,000. Steward Partners Investment Advisory LLC boosted its position in GlaxoSmithKline by 733.5% in the 4th quarter. Steward Partners Investment Advisory LLC now owns 67,396 shares of the pharmaceutical company’s stock valued at $2,390,000 after buying an additional 59,310 shares during the last quarter. Finally, California Capital Advisors Inc. purchased a new position in GlaxoSmithKline in the 4th quarter valued at about $210,000. 11.10% of the stock is owned by institutional investors.
A number of equities research analysts have recently issued reports on the stock. Zacks Investment Research upgraded shares of GlaxoSmithKline from a “hold” rating to a “buy” rating and set a $41.00 target price on the stock in a research note on Thursday, March 22nd. TheStreet lowered shares of GlaxoSmithKline from a “b-” rating to a “c” rating in a research note on Wednesday, February 7th. Kepler Capital Markets upgraded shares of GlaxoSmithKline from a “reduce” rating to a “hold” rating in a research note on Friday, February 9th. JPMorgan Chase restated a “neutral” rating on shares of GlaxoSmithKline in a research note on Monday, February 5th. Finally, Morgan Stanley upgraded shares of GlaxoSmithKline from an “underweight” rating to an “equal weight” rating in a research note on Thursday, March 22nd. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and five have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average target price of $40.21.
Shares of GlaxoSmithKline opened at $40.03 on Monday, Marketbeat reports. The stock has a market capitalization of $99.25 billion, a PE ratio of 13.90, a P/E/G ratio of 2.06 and a beta of 0.82. The company has a current ratio of 0.61, a quick ratio of 0.40 and a debt-to-equity ratio of 3.90. GlaxoSmithKline has a 1 year low of $34.52 and a 1 year high of $44.53.
GlaxoSmithKline (NYSE:GSK) last issued its earnings results on Wednesday, April 25th. The pharmaceutical company reported $0.68 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.70 by ($0.02). The company had revenue of $10.04 billion during the quarter, compared to analyst estimates of $10.26 billion. GlaxoSmithKline had a net margin of 3.50% and a return on equity of 144.84%. sell-side analysts forecast that GlaxoSmithKline will post 2.95 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, July 12th. Investors of record on Friday, May 11th will be paid a dividend of $0.5298 per share. The ex-dividend date is Thursday, May 10th. This represents a $2.12 annualized dividend and a yield of 5.29%. GlaxoSmithKline’s dividend payout ratio (DPR) is 72.92%.
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of vaccines, over-the-counter medicines, and health-related consumer products worldwide. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, dermatology, rare diseases, immuno-inflammation, and HIV, as well as vaccines.
Want to see what other hedge funds are holding GSK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GlaxoSmithKline (NYSE:GSK).
Receive News & Ratings for GlaxoSmithKline Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GlaxoSmithKline and related companies with MarketBeat.com's FREE daily email newsletter.